Tivic Health Systems Inc (TIVC) News

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form 8-K - Current report

Tivic Reports Year End 2024 Financial Results and Provides Overview of Strategy for Transformation and Growth

Pre-recorded Conference Call and Webcast to Follow Today at 1:30 PM PDT / 4:30 PM EDT Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified...

Form 8-K - Current report

Form 8-K - Current report

Tivic Health Files Patent For Optimized Electrical Stimulation of the Vagus Nerve

- Patent based on state-of-the-art science of vagus nerve stimulation approach shows greater effect from personalization of treatment - Tivic...

Form 8-K - Current report

Tivic Health Names Biotech Industry Veteran Michael K. Handley to Executive Leadership Team

Handley Joins as President of Tivic Biopharma and Chief Operating Officer of Tivic Health Following Its Licensing of Strategic Biopharma Assets...

Shares Of Micro Cap Biotech Surging On Acquisition Of Exclusive Worldwide Rights to Phase III TLR5 Agonist

Today was a big day for one small cap biotech company. The company announced that they had acquired worldwide exclusive license rights to a...

Form 8-K - Current report

Tivic Health Acquires Exclusive Worldwide Rights to Phase III TLR5 Agonist from Statera Biopharma

Broad licensing agreement accelerates Tivic’s transformation into a diversified therapeutics company, adds late-stage immunotherapeutic to...

Form 8-K - Current report

CEO Letter to Shareholders Issued by Tivic Health

Provides updates on vagus nerve stimulation (VNS) program and expectations for 2025 Tivic Health® Systems, Inc. (Nasdaq: TIVC), a health tech...

Form 8-K - Current report

Form PRE 14A - Other preliminary proxy statements